Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: A prospective, randomized clinical trial in a university hospital

Clinical Microbiology and Infection

Volumn 16, Issue 8, 2010, Pages 1252-1257

  Saltoglu, N ^a   Dalkiran, A ^b   Tetiker, T ^b   Bayram, H ^b   Tasova, Y ^b   Dalay, C ^b   Sert, M ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Cilastatin; Diabetic foot infection; Imipenem; Piperacillin; Tazobactam

Indexed keywords

CILASTATIN PLUS IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CILASTATIN; CILASTATIN, IMIPENEM DRUG COMBINATION; DRUG COMBINATION; IMIPENEM; PENICILLANIC ACID; PIPERACILLIN;

ADULT; AGED; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIUM ISOLATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC FOOT; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOOT AMPUTATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC DISEASE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NAUSEA; NEPHROTOXICITY; OSTEOMYELITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TREATMENT DURATION; UNIVERSITY HOSPITAL; WOUND CARE; AMPUTATION; ANALOGS AND DERIVATIVES; BACTERIA; BACTERIAL INFECTIONS; CLASSIFICATION; COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; ISOLATION AND PURIFICATION; MIDDLE AGED; RECURRENT DISEASE; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMPUTATION; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CILASTATIN; DIABETIC FOOT; DRUG COMBINATIONS; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; IMIPENEM; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77954857962     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.03067.x     Document Type: Article

References (28)

1. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabet Care 2006, 29:1288-1293.
2. Apelqvist J, Bakker K, van Houtum WH, Schaper NC. Practical guidelines on the management and prevention of the diabetic foot: based upon the International Consensus on the Diabetic Foot (2007) Prepared by the International Working Group on the Diabetic Foot. Diabet Metab Res Rev 2008, 24(suppl 1):S181-S187.
3. Lipsky BA, Berendt AR, Deery HG. Diagnosis and treatment of diabetic foot infections. Guidelines for diabetic foot infections. Clin Infect Dis 2004, 39:885-910.
4. Frykberg RG, Zgonis T, Armstrong DG. American college of foot and ankle surgeons. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg 2006, 45(suppl 5):S1-S66.
5. Brem H, Sheehan P, Rosenberg HJ, Schneider JS, Boulton AJM. Evidence based protocol for diabetic foot ulcers. Plast Reconstr Surg 2006, 117(suppl 7):193-209.
6. Lipsky BA. Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immunol Med Microbiol 1999, 26:267-276.
7. Ramsey SD, Newton K, Blough D. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabet Care 1999, 22:382-387.
8. Rao N, Lipsky BA. Optimising antimicrobial therapy in diabetic foot infections. Drugs 2007, 67:195-214.
9. Nelson EA, O'Meara S, Golder S. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabet Med 2006, 23:348-359.
10. Frykberg RG. An evidence-based approach to diabetic foot infections. Am J Surg 2003, 186(suppl 5A):44S-54S. discussion 61S-64S
11. Lipsky BA, Armstrong DG. Ertapenem versus piperacillin/tazobactam for diabetic foot infections. (SIDESTEP): prospective, randomised, controlled, double-blinded multicenter trial. The Lancet 2005, 366:1695-1703.
12. Lipsky BA. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabet Metab Res Rev 2004, 20(suppl 1):S68-S77.
13. Bouter KP, Visseren FLJ, Van Loenhout RMM, Bartelink AKM, Erkelens DW, Diepersloot RJA. Treatment of diabetic foot infection: an open randomised comparison of imipenem/cilastatin and piperacillin/clindamycin combination therapy. Int J Antimicrobial Agents 1996, 7:143-147.
14. Erstad BL, McIntyre KE, Mills JL. Prospective, randomized comparison of ampicillin/sulbactam and cefoxitin for diabetic foot infections. Vascular Surg 1997, 31:419-442.
15. Grayson ML, Gibbons GW, Habershaw GM. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatining foot infections in diabetic patients. Clin Infect Dis 1994, 18:683-693.
16. Zeillemaker AM, Veldkamp KE. Piperacillin/tazobactam therapy for diabetic foot infection. Foot & Ankle Inter 1998, 19:169-172.
17. Harkless L, Boghossian J, Pollak R. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect (Larchmt) 2005, 6:27-40.
18. Ge Y, MacDonald D, Hait H, Lipsky BA. Microbiological profile of infected diabetic foot ulcers. Diabetic Med 2002, 19:1032-1035.
19. Carvalho CB, Neto RM, Araqao LP, Oliveira MM, Noqueira MB, Forti AC. Diabetic foot infection. Bacteriologic analysis of 141 patients. Arq Bras Endocrinol Metabol 2004, 48:398-405.
20. Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007, 45:2819-2828.
21. Grayson ML. Diabetic foot infections. Antimicrobial therapy. Infect Dis Clin North Am 1995, 9:143-161.
22. Gadepalli R, Dhawan B, Sreenivas V, Kapil A, Ammini AC, Chaudhry R. A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care 2006, 29:1727-1732.
23. Shankar EM, Mohan V, Premalatha G, Srinivasan RS, Usha AR. Bacterial etiology of diabetic foot infections in South India. Eur J Intern Med 2005, 16:567-570.
24. Armstrong DG, Lipsky BA. Advances in the treatment of diabetic foot infections. Diabet Tech & Therap 2004, 6:167-177.
25. Motta RN, Oliveira MM, Megahaes PS. Plasmid mediated extended spectrum beta lactamase producing strains of Enterobacteriacea isolated from diabetic foot infections in a Brasilian diabetic center. Braz J Infect Dis 2003, 7:129-134.
26. Brodsky J, Schneidler C. Diabetic foot infections. Orthopedic Clin North Am 1991, 22:473-489.
27. Caputo GM, Joshi N, Weitekamp MR. Foot infections in patients with diabetes. Am Fam Physician 1997, 56:195-202.
28. Pinzur MS, Slovenkai MP, Trepman E, Shields NN. Guidelines for diabetic foot care: recommendations endorsed by the diabetes committee of the american orthopaedic foot and ankle society. Foot Ankle Int 2005, 26:113-119.